Search research articles
Contact Us
Filters
Showing results (91-100 of 116) with videos related to
Page
of 12
Sort By:
American Heart Journal
|
March 1, 1997
Influence of local delivery of the protein tyrosine kinase receptor inhibitor tyrphostin-47 on smooth-muscle cell proliferation in a rat carotid balloon-injury model
M Gottsauner-Wolf, Y Jang, A M Lincoff, et al.
Journal of the American College of Cardiology
|
November 18, 2000
Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial
H C Herrmann, D J Moliterno, E M Ohman, et al.
Circulation
|
July 27, 2001
Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT
B E Tardiff, L K Jennings, R A Harrington, et al.
The New England Journal of Medicine
|
July 29, 1999
Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators
A M Lincoff, R M Califf, D J Moliterno, et al.
Journal of the American College of Cardiology
|
February 6, 1999
Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II
B E Tardiff, R M Califf, J E Tcheng, et al.
The Annals of Thoracic Surgery
|
September 2, 2000
Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing
A M Lincoff, L A LeNarz, G J Despotis, et al.
The American Journal of Cardiology
|
November 13, 2001
Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study)
J E Tcheng, J D Talley, J C O'Shea, et al.
Circulation
|
February 23, 2000
Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators
N S Kleiman, A M Lincoff, G C Flaker, et al.
Circulation
|
April 20, 1999
Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade
A M Lincoff, J E Tcheng, R M Califf, et al.
Circulation
|
September 7, 2000
Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators
M T Roe, R A Harrington, D M Prosper, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 116) with videos related to
Sort By:
Page
of 12
American Heart Journal
|
March 1, 1997
Influence of local delivery of the protein tyrosine kinase receptor inhibitor tyrphostin-47 on smooth-muscle cell proliferation in a rat carotid balloon-injury model
M Gottsauner-Wolf, Y Jang, A M Lincoff, et al.
Journal of the American College of Cardiology
|
November 18, 2000
Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial
H C Herrmann, D J Moliterno, E M Ohman, et al.
Circulation
|
July 27, 2001
Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT
B E Tardiff, L K Jennings, R A Harrington, et al.
The New England Journal of Medicine
|
July 29, 1999
Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators
A M Lincoff, R M Califf, D J Moliterno, et al.
Journal of the American College of Cardiology
|
February 6, 1999
Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II
B E Tardiff, R M Califf, J E Tcheng, et al.
The Annals of Thoracic Surgery
|
September 2, 2000
Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing
A M Lincoff, L A LeNarz, G J Despotis, et al.
The American Journal of Cardiology
|
November 13, 2001
Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study)
J E Tcheng, J D Talley, J C O'Shea, et al.
Circulation
|
February 23, 2000
Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators
N S Kleiman, A M Lincoff, G C Flaker, et al.
Circulation
|
April 20, 1999
Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade
A M Lincoff, J E Tcheng, R M Califf, et al.
Circulation
|
September 7, 2000
Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators
M T Roe, R A Harrington, D M Prosper, et al.
Page
of 12